IAM earnings analysis
10-Q · Filed November 19, 2026 · Our reading of the company's report
The latest report
The quarter reflects a high-risk clinical-stage profile: collaboration revenue was $11.351 million, while reported EPS was negative $6.23 and nine-month net losses increased to $88.6 million from $54.6 million.…
Read full summary
The quarter reflects a high-risk clinical-stage profile: collaboration revenue was $11.351 million, while reported EPS was negative $6.23 and nine-month net losses increased to $88.6 million from $54.6 million. Liquidity improved materially through the approximately $156.0 million of IPO net proceeds, with management estimating funding into or through the fourth quarter of 2028, but the company remains dependent on additional capital, partnerships, and successful clinical execution. The most material updated risks are widening losses, concentrated manufacturing dependencies—including China-linked suppliers—and substantial post-IPO share overhang.
Reported figures
- Earnings per share
- $-6.23
What stood out
-
$11.351M of collaboration revenue
Third-quarter collaboration revenue was $11.351 million. The filing does not provide sufficient prior-period or prior-year revenue figures in the supplied extract to quantify the period-over-period trend.
-
Cash runway extends through Q4 2028
Cash and cash equivalents were $252.0 million as of September 30, 2026. Management estimates this balance will fund operating expenses and capital expenditures into or through the fourth quarter of 2028.
-
IPO added approximately $156.0M net cash
The IPO generated approximately $156.0 million of net proceeds after approximately $16.5 million of offering expenses, strengthening liquidity after quarter-end.
-
IAM217 cleared for planned Phase 1/2 trial
The FDA’s safe-to-proceed letter followed the September 30, 2026 IND submission for IAM217, allowing the planned Phase 1/2 trial to proceed, subject to trial execution.
-
Disclosure controls remain effective
Management reported that disclosure controls and procedures were effective at the reasonable-assurance level as of the end of the reporting period, with no material change in internal control over financial reporting during the quarter.
-
IAM1363 clinical program advancing
IAM1363 remained in a Phase 1/2 trial, with monotherapy expansion and combination cohorts actively enrolling. As of the August 31, 2026 data cutoff, 68 subjects had received 960 mg once daily monotherapy dosing.
What to watch
-
Losses are widening and profitability remains remote
The company reported net losses of $88.6 million for the nine months ended September 30, 2026, versus $54.6 million in the comparable 2025 period, and an accumulated deficit of $283.8 million. Management states it expects significant expenses and increasing operating losses for the foreseeable future.
-
Single-source and China-linked manufacturing exposure
The company relies on a single contract manufacturer for IAM1363 drug substance and does not have a qualified second-source supplier. In addition, a significant portion of third-party manufacturing is concentrated with China-based or China-affiliated providers, including WuXi AppTec, which the filing says is at high risk of designation under the BIOSECURE Act.
-
Post-IPO dilution and lock-up expiration risk
The filing newly emphasizes public-company dilution and resale pressure following the IPO: 38,871,378 shares, or approximately 79.4% of outstanding shares, were restricted as of November 16, 2026, with IPO lock-ups set to expire on April 12, 2027. Insiders and other holders above 5% collectively owned approximately 34.8% of outstanding shares.
Management's outlook
No formal numeric revenue or EPS guidance was provided. Management estimates that cash and cash equivalents will fund operating expenses and capital expenditures into or through the fourth quarter of 2028; the estimate is based on assumptions that could prove incorrect. The company also anticipates submitting the IAM-C1 IND application in the fourth quarter of 2026 and initiating a Phase 1/2 trial in early 2027, subject to regulatory clearance.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every IAM trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.